Political Quotes

On the recordFebruary 9, 2012
I yield myself such time as I may consume. Madam Speaker, Members of the House, we come here this morning as the leaders of the Judiciary Committee, and I have to assume that the chairman of the Judiciary Committee, Mr. Smith, like myself, is deeply disappointed that we're bringing a bill that we've never had a hearing on before the committee before the Congress for disposition. {time} 0920 Here was a bill referred to six committees: Financial Services, Agricultural, Judiciary, House Administration, Ethics, and the Rules Committee. Only one hearing was held in one of these committees on this measure. It's never been before Judiciary or any other committee, and so I want to begin by complimenting the author of this measure, the ranking member, former chairwoman of the Rules Committee, the gentlelady from New York, Louise Slaughter, for a serious and important amendment that has never been treated fairly. Now, I don't know what the explanation is. Maybe we can get to it during this proceeding. But I think that this is not the way that we want to move forward with a bill that was supposed to get to an insider trading ban that everybody wanted, because there's no reporting requirement in this bill. So, I will reserve the balance of my time and look forward to the discussion.
Said by
John Conyers
Democratic · Michigan
Source
govinfo.gov
Feb 9, 2012

Share

More from John Conyers

Oct 24, 2017

Members of the House, this amendment makes a bad bill even worse. To begin with, it would prohibit cy-pres distributions pursuant to which parties attempt to find the next best use of funds that remain after a class action settlement has…

govinfo.gov
Oct 25, 2017

Unfortunately, the current administration in swift fashion abandoned America's bipartisan leadership in this arena.

congress.gov
Mar 11, 2019

Yes, they tell me there is a chance it could very well be struck down. But we will go ahead and run that risk.

congress.gov
Jul 26, 2017

We should of course remain vigilant about pay-for-delay schemes, whereby branded drug manufacturers pay generic manufacturers to delay the entry of a version of branded drugs as the patent on the branded drug expires.

congress.gov

Other voices in this conversation